Interim Phase 2/3 Analysis: QRX003 Continues to Show Promise in Netherton Syndrome

Quoin Pharmaceuticals Ltd.’s QRX003 lotion performed well in an interim analysis of a Phase 2/3 study of Netherton Syndrome patients.

QRX003 is an investigational topical serine protease inhibitor lotion. Quoin expects to complete recruitment of all 20 participants in CL-QRX003-004 by the end of 2026 and report top-line data in the second quarter of 2027.

QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations by the US Food and Drug Administration (FDA), and Orphan Drug Designation in the European Union and Japan. QRX003 lotion (4%) is currently being evaluated in whole-body clinical trials in patients with Netherton Syndrome, including the Phase 2/3 study CL-QRX003-004.

About CL-QRX003-004

CL-QRX003-004 is a Phase 2/3, multicenter, baseline-controlled, open-label study evaluating the safety, tolerability, and efficacy of QRX003 4% lotion applied twice daily to all of the body excluding the scalp in patients with Netherton Syndrome. The study will enroll approximately 20 evaluable participants aged four years and older across multiple clinical sites in both the US and the UK.

This interim analysis covers the first six participants to complete the 12-week treatment period. The cohort comprised three male and three female participants ranging in age from 11 to 52 years

Treatment duration is 12 weeks, followed by a four-week post-treatment End of Study visit. Subjects must discontinue all standard of care therapy, including topical and systemic prescriptions, for the duration of the study.

The primary endpoint of 1-grade improvement or greater for Investigator Global Assessment (IGA) on all of the treatment area met the pre-specified alpha-adjustment for interim analysis with statistical significance.

Four of six (participants achieved the target 1-grade or greater improvement across all of the treatment area in IGA from baseline at Week 12. Two of those four participants achieved a 2-grade or greater IGA improvement across all the treatment area.

Key secondary endpoints, a Global Statistical Test of Global Impression of Change, achieved statistical significance at Week 12 with a mean change of -1.5.

All three participants with moderate-to-severe pruritus at baseline achieved a clinically meaningful greater than 3-grade improvement in Worst Itch Numeric Rating Scale (WI-NRS, scale 0-10) at Week 12. One participant had a greater than 6-grade improvement, the study showed.

For the Ichthyosis Area and Severity Index (IASI), improvements ranging from 31-87% reduction in severity from baseline were recorded after 12 weeks of treatment with QRX003. These results mirrored those for the IGA with the same four participants recording clinically meaningful improvements for both endpoints. 

“These interim results provide further objective evidence that QRX003 has the potential to change the course of Netherton Syndrome,” says Michael Myers, PhD, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals, in a news release.

Interim Results

Primary Endpoint: IGA 1-Grade or Greater Improvement from Baseline

 

VisitResponders (N)

 

Percent (95% CI)P-Value
Week 12
End of Treatment
4 (6)66.67% (22.28%, 95.67%)0.0087
  • Pre-specified alpha adjustment for interim evaluation (p=0.0087 vs. α=0.0215)
  • Null hypothesis was 1 patient responder
Global Statistical Test- Global Impression of Change (GIC)

 

Visit

 

Statistics

 

Observed Value

 

Week 12N6
Mean (SD)-1.5 (0.82)
95% Confidence Interval(-2.3, -0.6)
One Sample T-Test P-Value0.0070

 

WI-NRS: 2-Grade or Greater Improvement from Baseline

 

VisitResponders (N)

 

Percent (95% CI)P-Value
Week 12

 

3 (6)50.00% (11.81%, 88.19%)0.0623